MYMD - Earnings announcements

MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions, announced statistically significant positive topline Phase 2 results for its next generation Oral TNF-α inhibitor MYMD-1 in Sarcopenia/Age-Related Frailty earlier this week. In conjunction with its release, the company also announced it will hold a conference call today, August 2nd, at 4:30pm ET to discuss the results. To participate in the conference call, please register here. A webcast can also be accessed under the ‘Events & Presentations' section on the Investors page at w

- MYMD-1 significantly reduced serum levels of chronic inflammatory markers and met all primary pharmacokinetic and secondary safety and tolerability endpoints across multiple doses over 28 days of treatment - MYMD-1 demonstrated statistical significance across three biomarkers: TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) - First Oral TNF-α inhibitor, if approved, would offer potential patient benefit in large markets - Company to present the data to FDA and intends to advance the clinical program for MYMD-1; will hold conference call on August 2, 2023, at 4:30 PM Eastern Time MyMD Pharmaceuticals, Inc.® (NASDAQ:MYMD) ("MyMD" or the "Company"), a clinical stage pharmaceutica